@ -26,7 +26,7 @@ Attempt to build a "cannonical" probabalistic model of the clinical trials proce
# Models
The general benefit I can provide is to:
- Create a straightforward replication/update pathway.
- Describe the model in terms of conditional probability distributions (not expectations).
- Model based on information known at the beginning of the trial.
- This might allow me to escape [[EK]]'s markov modeling approach for phase transitions.